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Patients presenting with symptoms of chronic stable angina represent a relatively 
significant portion of general population, especially among older aged. Among people 
45-54 years old, stable angina is reported between 2-5% in men and 0.5-1% in women, 
while among people 65-74 years old the corresponding incidence is reported 11-20% 
for men and 10-14% for women respectively. In >50% of these patients angina limits 
significantly everyday activities leading to premature retirement, according to various 
national health and insurance surveys.
Chronic stable angina is a slowly progressive disease and the patients show a 
relative mortality of approximately 2% per year, significantly lower than the mortal-
ity of patients with unstable acute coronary syndromes or vascular disease and only 
slightly higher than that of patients with several risk factors who are under treatment 
for primary prevention. Mortality among patients with stable angina is related to the 
extension and the severity of coronary artery disease (CAD), their left ventricular 
function, exercise capacity, nature of the symptoms and ECG findings both at rest 
and during stress.
The main objectives of the treatment of patients with chronic stable angina, as 
outlined in the current guidelines, are directed towards preventing myocardial infarc-
tion and death (thereby improving the “quantity” of life) as well as preventing further 
ischemia and related symptoms (thereby improving “quality” of life) [1]. Current stable 
angina treatment includes medical therapy, percutaneous coronary revascularization 
procedures (PCI) and surgical revascularization (CABG). A meta-analysis of six 
randomized trials of percutaneous coronary revascularization with plain old balloon 
angioplasty (POBA) showed that, compared to medical treatment, POBA offered 
more symptomatic relief in patients with stable angina, without any significant differ-
ence in the rate of death, acute MI or need for new PCI. There was only a trend for 
more CABG procedures among patients treated with POBA and this was attributed 
to an excess of ischemic complications [2]. It must be mentioned that recent technical 
advances such as stents or newer devices that could improve the efficacy of POBA 
and abolish this excess have not been used in these trials.
In another meta-analysis [3] of 11 randomized trials of PCI with implantation 
of bare metal stents (BMS), treatment of patients with stable angina by PCI showed 
no difference in death, acute myocardial infarction (MI), CABG or PCI procedures 
compared to medical treatment. Common finding in all these trials is that PCI shows 
no difference in death or MI compared to medical therapy, but a clear and sustained 
benefit in angina relief. As it is underscored also in MASS II trial results, neither PCI 
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nor CABG have ever been shown to improve the already excel-
lent survival of most patients with stable CAD treated with 
medical therapy and the main indication for revascularization 
of stable CAD patients is angina relief and restored quality of 
life [4]. As a consequence, in 2006 the American Heart As-
sociation as well as the European Society of Cardiology issued 
the current guidelines for the treatment of patients with stable 
angina. According to these guidelines, “revascularization in 
patients with angina CCS class I to IV despite medical therapy 
is a class IA recommendation and can be performed either by 
PCI, irrespectively of the extension of underlying CAD (espe-
cially in non diabetics) or by CABG, in cases of left main or 
three vessel disease and objective large ischemia. Either PCI 
or surgery may be considered as an effective option for treat-
ment of symptoms of these patients. Single or multivessel PCI 
can be performed with high success using stents, drug eluting 
or not, and the risk of death is estimated 0.3-1%. Compared 
with medical therapy, PCI does not provide survival benefit 
in stable angina but is more effective at reducing events that 
impair quality of life. Initial pharmacological approach may 
be taken in patients not at high risk and revascularization may 
be recommended for patients with suitable anatomy who do 
not respond adequately to medical treatment or those who 
wish to remain physically active”.
Last year the results of the COURAGE trial were pub-
lished in the New England Journal of Medicine, producing 
one of the biggest debates concerning the value of PCI in the 
treatment of patients with stable angina [5]. In this trial an 
hypothesis was tested, that PCI plus optimal medical therapy 
would be superior to optimal medical therapy alone. The 
primary end point of the study was death or non fatal MI, 
opposite to all up to now existing data that have shown no 
influence of either method to hard clinical end points. Sec-
ondary end points of the study were death, MI or stroke, new 
hospitalization for acute coronary syndrome, quality of life 
including angina and cost effectiveness.
This trial was performed in the USA and Canada and 2287 
patients were enrolled in it, mainly (83%) in USA Veterans 
or Canadian Hospitals usually not performing PCI or with a 
very low PCI volume. The 2287 patients enrolled was only a 
small percentage (6%) of the total 3553 patients screened for 
the study. The main reasons for exclusion from the study were 
class IV angina, failed medical therapy, low left ventricular 
ejection fraction, recent revascularization procedure, left 
main disease or not suitable anatomy, co-existing illness, 
complications of acute MI, restenosis post PCI, etc. This 
means that almost all the patients with high risk features who 
would gain benefit from revascularization were excluded and 
the remaining included population had a low annual risk of 
death, less than 1%. In this highly selected and relatively low 
risk population the hypothesis of the trial tested, opposite to 
all existing data, seems to be unreal.
Patients were randomized to a optimal medical therapy 
(OMT) with all the available pharmacologic agents along with 
regular weekly activity or to PCI plus optimal medical therapy 
(PCI+OMT). All patients, at five years follow up, found to 
be very compliant to the assigned medical therapy with levels 
of LDL cholesterol around 70 mg%, HDL cholesterol around 
40 mg%, normal blood pressure and regular moderate weekly 
activity (5x/week).
On the contrary, PCI treatment was not optimal, in fact 
it was substandard. Patients were treated in low PCI volume 
hospitals and by less experienced interventionists. From the 
total number of patients assigned to invasive treatment, PCI 
was performed in 4% of them and was successful in only 3% 
of the PCI cases (a percentage significantly smaller than the 
success rate achieved contemporarily in most experienced 
centers throughout the world). Stents were used in 86% of 
the cases and most of them (7%) were bare metal stents, 
which show greater restenosis rate and consequently relapse 
of symptoms and more adverse events than the new more 
effective in reducing post PCI major adverse cardiac events 
(MACE) drug eluting stents (DES), which were used in only 
3% of the patients. Around 47% of the patients with multives-
sel disease (371 out of 787) had incomplete revascularization, 
which has been correlated with less favourable outcome post 
PCI and even higher mortality rate. Finally, few patients 
received periprocedural infusion of platelet glucoprotein 
(Gp) IIb/IIIa inhibitors or adequate clopidogrel pre-loading, 
which has contributed in reducing periprocedural ischemic 
complications.
According to the results of the study, total mortality rate 
during 5 year follow up was found 7.6% for the PCI group and 
8.3% for OMT group (hazard ratio: 0.87, p=0.38). Since total 
mortality was used as the primary end point of the study and 
half (53%) of the total 180 deaths reported were non cardiac, 
it seems that the selection of all cause mortality was not ac-
curate because PCI would only be expected to reduce cardiac 
deaths. Despite that, PCI treatment was correlated with a non 
significant reduction of total death rate.
The 5-year survival free of death from any cause and MI 
did not differ among the two groups of patients (hazard ratio: 
1.05, p=0.62). As far as MI rate (any biomarker elevation) at 
5 years, it was found a little higher in the PCI group (13.2% 
versus 12.3% in OMT group) with a hazard ratio: 1.13, p=0.33. 
Nevertheless, it should be mentioned that spontaneous MI 
rates during follow up period were higher in the OMT group 
(11 versus 108 in PCI) and the total difference observed was 
due to more periprocedural MIs seen in the PCI group (35 
versus  in OMT) attributed to the lack of adequate antiplate-
let regimen used.
Considering the “hard” clinical end points of the study, 
PCI treatment versus OMT was found more effective in reduc-
ing non significantly death by 13% (7.6% vs 8.3%), spontane-
ous MI by 11% (.3% vs 10.4%) and highly significantly the 
revascularization rate by 40% (21.6% vs 31,6%, p<0.001). A 
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percentage of 74% of the PCI and 72% of the OMT patients 
were angina free at 5 years follow up, but if we consider the 
10% more patients of the OMT group crossing over to PCI, 
the difference of angina-free patients is quite significant at 5 
years (74% versus 62%) in favour of PCI treatment. Patients of 
the PCI group also compared to OMT used significantly less 
antianginal medication, such as nitrates or calcium blockers, 
during long term follow up.
From the above mentioned data it is quite obvious that 
the COURAGE trial, in accordance with all the previous 
well conducted studies, showed that compared to optimal 
medical therapy, PCI performed in patients with stable CAD 
offers no difference in mortality or MI rate but a great benefit 
in quality of life with less medication use and lower repeat 
revascularization rate [6].
Recently the results of the nuclear substudy of the COUR-
AGE trial have been published [7]. In this study myocardial 
ischemia reduction, evaluated by myocardial perfusion scintig-
raphy, was examined among patients pre and at a mean of 12 
months post treatment with PCI or OMT. Patients allocated 
to PCI showed a mean reduction by 2.7% of ischemic myocar-
dium, while patients on OMT showed a modest reduction of 
only 0.5% of ischemic myocardium (p<0.0001). A percentage 
of 33% of patients treated by PCI showed ischemia reduction 
in ≥5% of myocardium while only 1% of patients treated 
with OMT showed the same reduction (p=0.004). These new 
findings further support the use of PCI in the treatment of 
patients with stable CAD for improvement of their functional 
status and reduction of ischemic complications.
In conclusion, current valid evidence-based medicine 
guidelines in stable CAD propose PCI for better control of 
angina and improvement of functional status especially when 
DES are used. It is appropriate to treat patients without high 
risk noninvasive testing with anti-anginal therapy first and 
then refer those who fail medical therapy for assessment of 
myocardium at risk and eventual PCI. Post COURAGE trial 
nothing has changed. All high risk patients or patients with 
symptoms despite optimal medical therapy and suitable coro-
nary anatomy should undergo PCI. Patients who should not 
receive PCI today are the patients with no angina, no ischemia, 
no stenosis (because treatment of vulnerable plaque remains 
an unproven concept) or no hope.
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